CytomX Therapeutics (CTMX) Equity Ratio (2016 - 2025)
CytomX Therapeutics' Equity Ratio history spans 12 years, with the latest figure at 0.65 for Q4 2025.
- For Q4 2025, Equity Ratio rose 17366.71% year-over-year to 0.65; the TTM value through Dec 2025 reached 0.65, up 17366.71%, while the annual FY2025 figure was 0.65, 17366.71% up from the prior year.
- Equity Ratio reached 0.65 in Q4 2025 per CTMX's latest filing, down from 0.68 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.68 in Q2 2025 to a low of 0.41 in Q2 2023.
- Average Equity Ratio over 5 years is 0.0, with a median of 0.13 recorded in 2022.
- Peak YoY movement for Equity Ratio: plummeted 24204.87% in 2022, then surged 17366.71% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.0 in 2021, then tumbled by 24204.87% to 0.33 in 2022, then grew by 28.46% to 0.24 in 2023, then soared by 98.39% to 0.0 in 2024, then soared by 17366.71% to 0.65 in 2025.
- Per Business Quant, the three most recent readings for CTMX's Equity Ratio are 0.65 (Q4 2025), 0.68 (Q3 2025), and 0.68 (Q2 2025).